Abiraterone Acetate (NCT04947254)

Name: Abiraterone Acetate trial for Prostate Carcinoma (NCT04947254)
Uploaded: 2026-10-31T23:02:19.057Z
Duration: 1 min 26 s
Description: Abiraterone Acetate trial for Prostate Carcinoma (NCT04947254). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT04947254.

Androgen Ablation Therapy With or Without Niraparib After Radiation Therapy for the Treatment of High-Risk Localized or Locally Advanced Prostate Cancer: a one-minute explainerNCT049472541 min

Abiraterone Acetate trial for Prostate Carcinoma (NCT04947254). This is a short film with English narration. The transcript is on this page, and the written brief is separate.

What the film says

Read the transcript

This trial is for adult men with high-risk localized or regional prostate cancer, without distant metastases, planning radiation and hormone treatment. Prior prostate surgery or radiation excludes participation.

The idea: apalutamide and androgen deprivation precede and accompany radiation. Good responders continue these. Poor responders enter random assignment to continue them or switch to abiraterone, prednisone, androgen deprivation, and niraparib. Niraparib blocks PARP-mediated DNA repair. Required tissue samples assess response; researchers compare progression-free survival.

This phase 2 study plans 200 patients. Patrick Pilie leads at MD Anderson, Houston, the sole recruiting US site.

Public record; not medical advice.

Read the full brief →

Already in a trial?

It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.

Organize my trial

7-day free trial, then $9 a month. Cancel anytime.